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Aim: The authors examined a cohort of HIV-positive outpatients at the AIDS Center of Palermo 
University in Italy in order to identify factors related to the frequency of their visits to the out-
patient facility for health care services.
Methods: Two hundred and twenty-four HIV-infected subjects were enrolled in the study. 
Demographic and HIV disease characteristics were recorded and assessed with the number 
of days accessed to our outpatients unit in univariate and multivariate analyses. The potential 
relationship with immunological status was also analyzed stratifying the patients into groups 
according to their CD4+ T-cell counts ($500 vs ,500/mm3, and $200 vs ,200/mm3).
Results: Both univariate and multivariate analyses showed that duration of antiretroviral 
therapy ,5 years and hypertension were significantly associated with a CD4+ T-cell count 
of ,500/mm3, whereas geographic origin (Africa) was associated with a CD4+ T-cell count 
of ,200/mm3. Mean number of days the patients sought access to day-care services for labora-
tory tests was negatively associated with CD4+ T-cell count.
Conclusion: Patients with low CD4+ T-cell counts showed higher use of health care services, 
demonstrating how early HIV diagnosis can help to reduce health care costs. The CD4+ T-cell 
cut-off of 200 cells emphasizes the importance of identifying and managing HIV infection among 
hard-to-reach groups like vulnerable migrants. In our sample, the illegal status of immigrants 
does not influence the management of their HIV/AIDS condition, but the lack of European 
health card that documents the current antiretroviral status, could interfere with the efforts 
to eradicate AIDS. A better understanding of the major determinants of HIV treatment costs 
has led to appropriate large-scale actions, which in turn has increased resources and expanded 
intervention programs. Further guidance should be offered to hard-to-reach groups in order to 
improve early AIDS diagnosis, and procedures for identifying and managing these vulnerable 
subjects should be made available to care commissioners and service providers.
Keywords: HIV infection, CD4+ T-cell count, access to care, HIV outpatient service, hard-to-
reach groups, resource use
Introduction
The advent of antiretroviral therapy (ART) has effectively changed the clinical course 
of HIV and patient life expectancy. The 2013 Joint United Nations Programme on HIV 
and AIDS report estimated that 35 million people are living with HIV and 1.5 million 
have died of AIDS worldwide.1
The number of new infections, which is currently 2.1 million per year world-
wide, is falling.1 However, because of socioeconomic reasons, there are discernible 
disparities between subequatorial countries and other parts of the world. This is 
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demonstrated by differences in way and time of access to 
health care services in different countries.1
In Europe, access to health care is a key factor in promoting 
and safeguarding the individual’s health. In Western and 
Northern Europe as well as in the US, preventing transmission 
of HIV infection and attempting early diagnosis have become 
the order of the day. However, since 2007, European health 
care systems have been affected by the global economic 
crisis, resulting in changes involving access to health care 
and to preventive services. The biggest challenge is how to 
provide optimal care for HIV patients at the lowest possible 
cost. In the US, the RESPECT program sponsored by the 
American Centers for Disease Control and Prevention has 
provided guidelines about the identification of patients whose 
risk factors justify carrying out anti-HIV testing, and about 
correct diagnostic and therapeutic procedures. The problem 
of migration, mainly from sub-Saharan Africa, is an issue 
with which many European countries and Italy and Spain 
are currently contending; this reality inevitably contributes 
to the significant change in HIV epidemiology.2–4
Migrants represent an independent risk factor for HIV 
infection, and at the same time, they are more likely to receive 
a delayed diagnosis due to late presentation with the disease. 
This makes clinical management more onerous and health 
care costs higher. In 2010, 49% of new infections diagnosed 
in Europe were among migrants. The Dublin Declaration 
guarantees the right of citizens to ART.5,6
The delivery of health care services in Italy is patchy, and 
is financed and organized at a regional level; consequently, 
the cost of HIV treatment varies significantly across regions 
and between medical centers. In Southern Italy and in Sicily 
in particular, immigration can be considered an epidemio-
logically relevant phenomenon as far as health structures 
and institutional approaches are concerned, with an average 
of $24.1/100,000 new HIV infections per year.7
In this study, we examined a cohort of HIV outpatients 
in Southern Italy between 2011 and 2013 in order to iden-
tify the factors that determined their utilization of health 
care resources. Consequently, we propose a way to better 
control the costs of managing these patients. We evaluated 
key factors by dividing the patients according to their CD4+ 
T-cell counts.
Materials and methods
Design and setting
We conducted a retrospective study of 224 HIV-positive indi-
viduals who attended the Infectious Diseases Outpatient Clinic 
of the “Paolo Giaccone” University Hospital in Palermo, 
Italy, for follow-up blood tests related to their HIV status 
between 2011 and 2013. Demographic and HIV disease 
characteristics were recorded and assessed with the number 
of days patients sought access to our outpatients unit in 
univariate and multivariate analyses. Potential relationship 
between immunological status was also analyzed stratifying 
the patients into groups according to their CD4+ T-cell counts 
($500 vs ,500/mm3 and $200 vs ,200/mm3).
Approximately 700 patients are admitted to this clinic 
each year for HIV management. Committed to the prevention 
and care of HIV infection, it is the regional AIDS referral 
center. Between 2009 and 2013, 980 new cases of HIV infec-
tion were registered in Sicily (270 of these in Palermo), with 
an average incidence rate of 3.92/100,000 per year.8,9
Virological and immunological follow-up is performed 
every 3 or 6 months, depending on clinical and immunological 
parameters. Patients receive free comprehensive care, including 
treatment for opportunistic infections (including tuberculosis 
[TB]), macro- and micronutrient supplementation, psychoso-
cial counseling, adherence counseling, and education about 
prevention strategies, and defaulter tracing is also carried out. 
According to Italian, European, and International guidelines,10 
ART is typically initiated when CD4+ T-cell count is ,350/mm3 
(patients in clinical stage 3 or 4) and when CD4+ T-cell count 
is .350/mm3 but ,500/mm3. ART is recommended to pre-
vent transmission, or in the event of pregnancy, coinfections 
(hepatitis B virus–hepatitis C virus [HBV-HCV], HIV-AN, 
HIV-associated neurocognitive disorder [HAND]), or non-
AIDS-related tumor. On the contrary, when CD4+ T-cell count 
is .500/mm3, ART is recommended when there is a rapid 
decline in CD4+ T-cell count ($100/mm3 annually) or when the 
count of HIV-RNA is $100,000 copies/mL. During each visit 
to the clinic, adherence is assessed by self-report. Adherence is 
considered “perfect” when the patients indicate that they have 
taken every dose as prescribed since starting ART.
Patient medical records were collected and entered into 
a hospital medical record database.
Informed consent, including consent to publication of 
patient details, was signed by all individuals before they 
accessed the day health care services, in accordance with the 
Declaration of Helsinki. The study protocol was approved 
by the Ethics Committee of the “Paolo Giaccone” University 
Hospital in Palermo, Italy.
Patients
Data on patients who were followed up at the AIDS Center of 
the “Paolo Giaccone” University Hospital in Palermo, Italy, 
in the day care or outpatient facility between January 2011 
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and May 2013 were extracted from the hospital’s medical 
record database.
We gathered clinical documentation on 224 HIV-positive 
subjects with complete follow-up data for the under-review 
period. The following data were collected and entered into 
the specially designed database: (a) demographic and clini-
cal characteristics of patients: age, gender, geographic origin 
(namely patient’s geographical origin stated in their document 
certified by the Italian institutions), lifestyle habits (including 
educational level, drug abuse history, sexual behavior), body 
mass index (BMI), comorbidities such as HCV coinfection, 
osteoporosis biomarker, treatment for dyslipidemia (total 
cholesterol $300 mg/dL and total cholesterol-to-high-density 
lipoprotein ratio .5 in males and .4 in females), diabetes, 
renal function, and hypertension; (b) current CD4+ T lympho-
cyte counts (cells/µL) were determined by flow cytometry, 
and HIV RNA viral load (VL) was measured in plasma 
by reverse transcriptase polymerase chain reaction (Roche 
Amplicor; lower limit of quantitation 20 copies/mL, 1.3 log
10
) 
as previously reported;11 and (c) variables related to ART: date 
of ART initiation, total time on ART, antiretroviral (ARV) 
drugs received and degree of adherence, as well as protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors, 
and exposure to tenofovir and other ARV drugs (ie, ralte-
gravir, maraviroc). These data were obtained from medical 
records and previously published investigations.11–13
All patients except the treatment-naïve subjects had 
started ART during previous inpatient stays.
None of the migrants enrolled in the study had a general 
practitioner (GP).
statistical analysis
Statistical analysis of quantitative and qualitative data, 
including descriptive statistics, was performed for all items. 
Continuous data are expressed as mean ± standard deviation 
(SD), unless otherwise specified. Frequency analysis was 
performed with chi-square test or Fisher’s exact test, as 
needed. The intergroup differences were assessed by one-way 
analysis of variance and Mann–Whitney U statistic test for 
parametric and nonparametric variables, respectively.
Odds ratios (ORs) and their 95% confidence intervals 
(CIs) were calculated using the univariate and multivariate 
model of multinomial logistic regression analysis. Data were 
analyzed with Epi Info software (version 6.0; Centers for 
Disease Control and Prevention, Atlanta, GA, USA) and IBM 
SPSS Software version 21.0 (IBM Corporation, Armonk, 
NY, USA). All P-values were two sided, and P-values ,0.05 
were considered statistically significant.
Results
Table 1 depicts the patient parameters collected from the 
electronic medical record database.
Data were stratified according to CD4+ T-cell count, 
comparing the characteristics of patients with CD4+ T-cell 
counts $500 vs ,500/mm3 and $200 vs ,200/mm3. 
The average age of patients enrolled in the study was 
45.6±9.2 years; 163 were males (73%), and 61 females 
(27%); 26 outpatients were African immigrants (12%) 
(Table 1). Nineteen of the 224 patients showed HIV–HCV 
coinfections (8.5%) (Table 1). Fourteen patients were 
treatment-naïve (6.3%), and the average of current CD4+ 
T-cell count was 524±292 SD (median 476)/mm3, while 
mean HIV RNA VL was 1.82 (±1.16; median 1.3) log
10
 
copies/mL.
For the whole group, mean number of days of access 
to day-care services for laboratory tests (to evaluate stage 
of HIV and to monitor treatment) was 6.5 (±2.5) days for 
CD4+ T-cell count measurements and 9.6 (±3.5) for HIV 
RNA VL.
cD4+ T-cell count $500 vs ,500/mm3
For the patient groups with CD4+ T-cell counts of $500 
vs ,500/mm3, ,5 years of ARV treatment and mean 
number of days of access to day-care services for laboratory 
tests – to evaluate HIV stage and to monitor treatment – were 
negatively associated with CD4+ T-cell count (P=0.017 and 
P=0.026, respectively) (Table 1; Figure 1).
As far as biochemical and physical parameters were con-
cerned, hypertension was negatively associated with CD4+ 
T-cell count in the ,500/mm3 group (P=0.044) (Table 1).
Table 2 depicts the univariate and multivariate regres-
sion analysis of patients with CD4+ T-cell counts of $500 
vs ,500/mm3. Less than 5 years of ART (OR =2.01, 95% CI: 
1.15–3.53, P=0.015 and OR =2.21, 95% CI: 1.22–3.99, 
P=0.009, respectively) and hypertension were significantly 
associated with a CD4+ T-cell count of ,500/mm3 in both 
univariate and multivariate analyses (OR =2.20, 95% CI: 
1.02–4.75, P=0.044 and OR =2.380, 95% CI: 1.05–5.41, 
P=0.039, respectively).
Mean number of days of access to day-care services for 
laboratory tests was negatively associated with CD4+ T-cell 
count but only in univariate regression analysis.
cD4+ T-cell count $200 vs ,200/mm3
We identified African race (P=0.034), low BMI (P=0.001), 
and drug addiction (P=0.039) as significant risk factors in 
the ,200/mm3 patient group (Table 1).
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Table 3 depicts the univariate and multivariate 
regression analysis of patients with CD4+ T-cell counts 
of $200 vs ,200/mm3; we found a significant associa-
tion between ethnicity (African) and a CD4+ T-cell count 
of ,200/mm3 in both univariate and multivariate analyses 
(OR =3.19, 95% CI: 1.13–9.03, P=0.028 and OR =10.05, 95% 
CI: 1.84–54.9, P=0.008, respectively), while a significant 
association between drug addiction and CD4+ count was 
detected in univariate regression analysis only (Table 3).
Discussion
The growing demand for health care services depends on 
a number of factors: an increase in the life expectancy of 
HIV patients, management of age-related diseases which 
requires patients to be monitored two to four times a year 
for highly active ART efficacy/toxicity, ethnicity and mode 
of transmission, AIDS-related diseases, and the important 
role of prevention (testing and counseling).12,14
The mean CD4+ T-cell count of our patients was 524/mm3; 
therefore, we can consider them to be a well-managed popu-
lation of individuals treated for HIV, with CD4+ cell counts 
over 500/mm3, or in any case, with chronic HIV infection 
and high CD4+ T-cell levels.
Mean access to day-care services for laboratory tests to 
evaluate stage of HIV infection and to monitor treatment 
was 6.5 days for CD4+ T-cell count measurements and 9.6 
for HIV RNA VL.
These results, which refer to a 25-month follow-up period, 
comply with standard recommendations if we consider that 
Figure 1 number of days of accesses to the outpatients clinic according to cD4+ 
T-cell count.
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Table 2 Univariate and multivariate regression analysis of patients stratified by 500/mm3 cD4+ T-cell count
HIV with a CD4+ T-cell count ,500 vs $500/mm3
Univariate Multivariate
Exp(B) 95% CI P-value Exp(B) 95% CI P-value
Demographic/lifestyle characteristics
Age 0.996 0.97–1.02 0.775
Female gender 1.20 0.66–2.16 0.549
nationality 2.205 0.92–5.30 0.078
BMi 0.910 0.82–1.01 0.083
characteristics of hiV infection
naïve ArT 2.847 0.82–9.87 0.099
homosexual 0.608 0.32–1.14 0.122
Bisexual 1.959 0.87–4.40 0.103
heterosexual 1.813 0.97–3.39 0.063
ArT
,5 years 2.013 1.15–3.53 0.015 2.206 1.22–3.99 0.009
5–10 years 0.719 0.35–1.46 0.362
.10 years 0.627 0.36–1.08 0.090
Drug addiction 1.482 0.80–2.75 0.212
number of accesses for Vl 1.056 0.98–1.14 0.167
number of accesses for cD4+ 1.128 1.02–1.26 0.028 1.092 0.98–1.22 0.130
cO-hcV 1.601 0.61–4.23 0.342
Biochemical and physical parameters
Blood calcium 0.860 0.50–1.47 0.582
Blood phosphorus 1.076 0.89–1.30 0.446
25-hydroxyvitamin D (ng/ml) 1.021 0.99–1.05 0.142
creatinine 1.042 0.91–1.20 0.567
Parathormone 0.980 0.95–1.01 0.149
hypertension 2.205 1.02–4.75 0.044 2.380 1.052–5.41 0.039
Treatment of cholesterolemia 1.398 0.60–3.26 0.438
Note: Statistically significant values are shown in bold. 
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; VL, viral load; CO-HCV, HIV–HCV coinfections.
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our cohort consists of patients who are on ART and have 
undetectable VL levels. Regarding mean and standard 
deviation calculated for the number of days of access to 
health care services for VL monitoring, our data demonstrate 
the importance of ARV drug monitoring and management to 
assess indicators such as adherence and emergence of HIV 
drug resistance, and to estimate the time to viral suppression 
after initiating a first-line regimen.15,16
In our study, mean number of days of access to day care 
for laboratory tests was negatively associated with CD4+ 
cell counts. These findings provide further support for early 
combination ART initiation in order to reduce the costs of 
health care management.17,18
Stratifying the patients according to CD4+ T-cell count, 
the 500/mm3 cut-off value helps us to identify the factors that 
determine manner and time of access to health care for HIV 
patients, whereas the 200/mm3 cut-off shows the key high-risk 
HIV groups such as migrants vs natives and drug addiction 
categories and confirmed the higher frequency of AIDS events 
in these categories of patients, as reported in other studies and 
recently by the Italian ICONA cohort study group.19,20
Regarding patient comorbidities, only hypertension was 
significantly associated with CD4+ T-cell count, highlighting 
how we can identify the key factors that determine HIV 
patients’ use of health care services through monitoring other 
pathologies affecting these subjects, such as cardiovascular 
disease.21
But how are we to cope with increased demand for these 
health care resources in a time of economic crisis?
Our study demonstrates that two categories of patients – 
drug addicts and immigrants – make greater use of health 
care services.
Data on injection drug users per se emphasize the impor-
tance of sustained HIV prevention measures for this category 
of patients who generally have a poor prognosis.22–24
Nevertheless, we must stress the importance of managing 
the migrant population if we aim to reduce health care costs 
related to HIV infection.
Patients in the “frail patient” category and those with 
sociopsychological issues are most in need of health care. 
In particular, the influx of immigrants poses a real challenge 
to public health, other than a significant change in HIV 
Table 3 Univariate and multivariate regression analysis of patients’ characteristics stratified by 200/mm3 cD4+ T-cell count
HIV with a CD4+ T-cell count ,200 vs $200/mm3
Univariate Multivariate
Exp(B) 95% CI P-value Exp(B) 95% CI P-value
Demographic/lifestyle characteristics
Age 0.995 0.95–1.04 0.841
Female gender 1.18 0.46–3.03 0.727
ethnicity 3.194 1.13–9.03 0.028 10.052 1.84–54.9 0.008
BMi 0.854 0.75–0.97 0.014 1.080 0.94–1.24 0.267
characteristics of hiV infection
naïve ArT 0.663 0.08–5.76 0.710
homosexual 0.295 0.07–1.31 0.108
Bisexual 2.603 0.94–7.25 0.067
heterosexual 1.395 0.54–3.59 0.491
ArT
,5 years 0.522 0.22–1.24 0.142
5–10 years 0.198 0.03–1.52 0.119
.10 years 0.937 0.39–2.24 0.884
Drug addiction 2.667 1.10–6.49 0.031 3.959 0.79–19.8 0.094
number of accesses for Vl 0.951 0.84–1.08 0.429
number of accesses for cD4+ 0.950 0.80–1.13 0.554
cO-hcV 2.611 0.79–8.67 0.117
Biochemical and physical parameters
Blood calcium 0.656 0.25–1.74 0.397
Blood phosphorus 0.984 0.78–1.24 0.890
25-hydroxyvitamin D (ng/ml) 0.979 0.93–1.04 0.435
creatinine 0.985 0.87–1.12 0.815
Parathormone 0.949 0.87–1.04 0.228
hypertension 1.583 0.55–4.59 0.397
Treatment of cholesterolemia 0.335 0.04–2.60 0.296
Note: Statistically significant values are shown in bold. 
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; VL, viral load; CO-HCV, HIV–HCV coinfections.
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epidemiology. Available literature shows that utilization 
of health care services is a primary indicator of migrant 
integration.25
None of the migrants enrolled in the study had a GP, 
though some of them had been resident in the country for a 
long time. Generally speaking, not only migrants but also 
Italian natives are reluctant to go to their GP. The Italian 
National Health Systems are going through a phase of change, 
but patients still prefer to go to hospital rather than visit their 
GP. This has been found in a pediatric study that the first 
author has published.26
Many of the immigrant patients in the study had just 
arrived from Libya in a situation of humanitarian emergency, 
as continues to be the case today. They are then transferred 
to a migrant reception center where they do not have access 
to a GP. Even after being in the country for some time, 
because of their frequent lack of work, they are considered 
illegal immigrants. Moreover, without a permit to stay in 
the country, they cannot be assigned to a GP. Regarding the 
services we provide for these migrants, we want to stress that 
their status has never influenced ART decisions. Thanks to 
an exemption granted by the Italian state, these individuals 
receive the same treatment as Italian natives regardless of 
cost and based solely on the patient’s state of health. Unfortu-
nately, because there is no European health card for migrants, 
data about treatment that these patients received in other 
countries once they had started ART are not available. The 
same may be said for other pathologies such as TB. Today, 
data need to be updated to take into account the emergency in 
Syria, but in general, the incidence of AIDS among African 
subjects remains high, as the incidence of TB does.
The findings of this study have several limitations. First, 
we did not determine CD4+ nadir, so we cannot correct the 
data with other risk factors, and we cannot estimate the time 
passed from the first diagnosis and the beginning of ARV 
even if none of migrant population and most of Italian HIV 
patients had never had a CD4+ count before admission to 
our hospital. Second, our study shows all the limitations 
of retrospective studies, and the small number of patients 
could suggest that our data reflected a local epidemiological 
situation.
The Italian government recognizes that migrants are 
vulnerable to social stigma, lack of community support, iso-
lation, racism, and discrimination for being an HIV-positive 
migrant. Nevertheless, HIV testing for migrants is not 
explicitly recommended in Italy. For this reason, from 2009 
to 2013, the ARTEMIS project was established to provide 
a program of social and health integration. COA-ISS data 
show an increase in the rate of new HIV infections among 
migrants compared to 1996, and a higher incidence of 
TB–HIV coinfection (particularly in patients from Eastern 
Europe).27,28
Total delay in diagnosis and initiation of effective treat-
ment depends on two separate, but in some cases concomi-
tant, elements: the delay attributable to the patient and the 
delay attributable to the health care system.
Delay attributable to the patient may be due to many 
factors, including demographics (gender, age), level of 
education, socioeconomic factors (poverty, loss of income or 
employment), awareness of the symptoms of disease, logistic 
factors (accessibility of health services, the structure chosen 
for first login), stigma associated with infectious disease, and 
in some populations, cultural and/or religious bias.
Delay attributable to the health care system depends on 
organizational aspects, such as weaknesses in the service 
network, lack of coordination and lack of effective and timely 
flow of information, lack of awareness of the clinical problem 
within the service network, or infrequent use of rapid diagnostic 
tools. A “vicious cycle” of repeated access to the same structure 
or structures of the same level with little diagnostic capacity is 
one of the main risk factors for delayed diagnosis.
Scientific evidence shows that in countries with a low 
incidence of the disease, the presence of problematic, vul-
nerable, and socially marginalized groups is a determining 
factor of delays in diagnosis and in initiating appropriate 
treatment, and may represent an epidemiologically relevant 
source of HIV transmission.
Migrants and refugees from countries with a high inci-
dence of HIV and other coinfections such as TB are exposed 
to difficulties related to language and cultural barriers, espe-
cially in the early years of their stay in Italy; these factors 
constitute a substantial part of the so-called vulnerable 
communities.29,30
Sicily’s regional health policy lacks the involvement 
of cultural associations that can raise awareness and direct 
migrants to preventive health care services. Most of the 
immigrants diagnosed with HIV are pregnant women who 
have undergone tests for sexually transmitted diseases. The 
delay in diagnosis together with the difficulty of access to 
preventive health care services may mean that these patients 
at diagnosis exhibit other HIV-related diseases resulting in a 
strong burden for the health care system.27,31
Conclusion
A better understanding of the major determinants of HIV 
treatment costs has led to appropriate large-scale actions, 
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which has increased resources and expanded intervention 
programs. As is the case for TB, further guidance needs to 
be offered to hard-to-reach groups in order to diagnose AIDS 
earlier,32,33 and procedures for identifying and managing 
these vulnerable subjects should be made available to care 
commissioners and service providers.34
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